• LAST PRICE
    0.8300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.8212/ 10
  • Ask / Lots
    0.8500/ 10
  • Open / Previous Close
    0.8103 / 0.8300
  • Day Range
    Low 0.8103
    High 0.8685
  • 52 Week Range
    Low 0.5000
    High 1.6200
  • Volume
    534,847
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.83
TimeVolumeATOS
09:32 ET181760.8103
09:33 ET210000.845
09:35 ET63500.8426
09:37 ET15850.8327
09:39 ET7800.83
09:46 ET13620.8289
09:48 ET11100.82
09:50 ET1000.8289
09:51 ET7500.8289
09:53 ET43200.8289
09:55 ET6000.8201
09:57 ET1040.8252
10:00 ET74980.82505
10:02 ET4050.8201
10:04 ET1200.8299
10:06 ET1000.8265
10:08 ET10080.826
10:09 ET14000.8251
10:15 ET1000.8251
10:20 ET1000.8256
10:22 ET11000.8288
10:24 ET6800.8288
10:26 ET3600.828616
10:36 ET9740.8204
10:38 ET1000.828699
10:40 ET13000.8287
10:44 ET7540.8287
10:45 ET1800.8287
10:56 ET7000.8287
11:00 ET31000.8441
11:02 ET2500.83275
11:03 ET51760.85
11:05 ET2000.85
11:07 ET102400.849899
11:16 ET17090.849899
11:18 ET22000.8401
11:20 ET71740.835951
11:21 ET2000.84
11:23 ET1000.821
11:25 ET24550.8465
11:27 ET5000.8496
11:36 ET5000.8454
11:38 ET6030.8456
11:39 ET1000.8425
11:41 ET2000.8401
11:43 ET27550.8456
11:45 ET1000.8428
11:48 ET4370.840001
11:50 ET5000.84085
11:52 ET5000.8395
11:54 ET15000.85
11:57 ET1000.835
12:01 ET64360.845
12:03 ET1000.845
12:08 ET12000.845
12:10 ET180130.844886
12:12 ET1141670.8557
12:14 ET72400.86
12:17 ET111190.856051
12:19 ET29000.856349
12:24 ET104360.8531
12:26 ET183640.86
12:28 ET14000.8668
12:30 ET9000.8663
12:32 ET3000.8668
12:33 ET12000.868
12:35 ET141070.8655
12:37 ET2000.8655
12:44 ET10000.8649
12:46 ET38000.8655
12:48 ET3500.8646
12:51 ET385080.8537
01:00 ET100000.8637
01:02 ET8000.86
01:04 ET51270.8511
01:06 ET32710.8634
01:08 ET4550.8576
01:09 ET1000.86
01:11 ET2000.86
01:13 ET2000.86
01:18 ET3230.855501
01:20 ET75730.851657
01:22 ET103500.8525
01:24 ET3000.851
01:27 ET17410.8507
01:29 ET1000.8473
01:33 ET10000.848086
01:36 ET3000.8453
01:38 ET12000.845398
01:40 ET7090.8496
01:42 ET21650.8496
01:44 ET17360.849193
01:45 ET18680.8373
01:47 ET2000.8315
01:51 ET7000.85
01:54 ET11500.8462
01:56 ET2000.85
02:00 ET39000.8499
02:02 ET16000.85
02:05 ET1000.8437
02:07 ET2000.85
02:09 ET30720.8499
02:16 ET22000.8402
02:21 ET3000.85
02:23 ET45000.842739
02:25 ET17000.85
02:27 ET77600.84
02:30 ET138720.832001
02:32 ET21670.83
02:36 ET7050.830088
02:38 ET19470.8391
02:43 ET5000.8301
02:52 ET1000.84
02:56 ET5000.835
02:57 ET5000.8351
03:01 ET11000.84
03:10 ET1000.8311
03:14 ET2200.8311
03:15 ET4000.836
03:17 ET1250.8311
03:19 ET2000.8357
03:24 ET11880.836
03:28 ET2000.8357
03:30 ET2000.8357
03:32 ET3100.8357
03:33 ET3000.8376
03:39 ET1000.836
03:50 ET1000.836
03:51 ET15310.8335
03:53 ET1000.8313
03:55 ET6330.836
03:57 ET157500.848
04:00 ET156070.83
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesATOS
Atossa Therapeutics Inc
105.1M
-4.3x
---
United StatesDARE
Dare Bioscience Inc
106.0M
-3.5x
---
United StatesIFRX
InflaRx NV
97.2M
-2.6x
---
United StatesCAPR
Capricor Therapeutics Inc
105.0M
-3.7x
---
United StatesNCNA
NuCana PLC
83.5M
-2.3x
---
United StatesMYMD
MyMD Pharmaceuticals Inc
101.4M
-6.7x
---
As of 2023-02-04

Company Information

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. It is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.

Contact Information

Headquarters
107 Spring StSEATTLE, WA, United States 98104-1005
Phone
206-588-0256
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Steven Quay
Chief Financial Officer, General Counsel, Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$105.1M
Revenue (TTM)
$0.00
Shares Outstanding
126.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.24
EPS
$-0.19
Book Value
$1.09
P/E Ratio
-4.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.